Mixed Results on Early Inhaled Budesonide in Very Preterm Infants

Infants given inhaled budesonide versus placebo were less likely to be diagnosed with bronchopulmonary dysplasia but equally likely to die.

Efforts are ongoing in the development of therapies to reduce the considerable morbidity associated with bronchopulmonary dysplasia (BPD) in infants surviving extreme prematurity.

In an industry-funded, multinational, randomized, controlled trial, researchers evaluated outcomes with early administration (within 24 hours of birth) of inhaled budesonide (200 µg/puff) or inhaled placebo in 856 infants born at gestational ages of 23 weeks and 0 days to 27 weeks and 6 days. Infants were administered two puffs every 12 hours for 2 weeks followed by one puff every 12 hours until the study drug was stopped.

The diagnosis of BPD (continued ventilator support or oxygen dependence) at 36 weeks' gestational age occurred in 27.8% of surviving infants comp…

Reviewing Author

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

F. Bruder Stapleton, MD

Disclosures

Consultant/Advisory BoardCareer Physician

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesAmerican Society of Pediatric Nephrology Foundation (Chair)

Mixed Results on Early Inhaled Budesonide in Very Preterm Infants

Topics

Reviewing Author